Invitae Co. (NYSE:NVTA – Get Free Report) has been given an average rating of “Strong Sell” by the five brokerages that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell rating and two have issued a hold rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $2.08.
NVTA has been the subject of a number of research reports. StockNews.com cut Invitae from a “hold” rating to a “sell” rating in a research note on Thursday. Raymond James lowered Invitae from a “market perform” rating to an “underperform” rating in a report on Monday, May 15th. The Goldman Sachs Group dropped their price target on Invitae from $1.50 to $1.00 and set a “sell” rating on the stock in a report on Friday, July 21st. Finally, Piper Sandler lowered their target price on Invitae to $1.50 and set an “underweight” rating on the stock in a research note on Tuesday, August 15th.
Get Our Latest Report on Invitae
Invitae Trading Up 4.1 %
Institutional Trading of Invitae
Large investors have recently added to or reduced their stakes in the stock. Strategic Blueprint LLC purchased a new position in shares of Invitae in the 1st quarter worth about $25,000. Veritable L.P. purchased a new position in shares of Invitae in the 1st quarter worth about $25,000. Versor Investments LP purchased a new position in Invitae in the 2nd quarter worth about $27,000. Aigen Investment Management LP purchased a new position in Invitae in the 4th quarter worth about $28,000. Finally, Private Advisor Group LLC raised its position in Invitae by 114.1% in the 2nd quarter. Private Advisor Group LLC now owns 25,012 shares of the medical research company’s stock worth $32,000 after buying an additional 13,330 shares during the last quarter. Institutional investors own 70.10% of the company’s stock.
About Invitae
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.
Featured Articles
- Five stocks we like better than Invitae
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 2 Stocks to Get You Ready for the Holiday Season
- How to Invest in the Healthcare Sector
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- What is a Special Dividend?
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.
